ARSACS: Clinical Features, Pathophysiology and iPS-Derived Models

Area of Science:

• Neuroscience
• Genetics
• Neurology

Background:

• Autosomal-recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset neurodegenerative disease linked to SACS gene mutations.
• Initially identified in French Canadian populations, ARSACS is now recognized as a frequent cause of recessive ataxia globally.
• Key clinical manifestations include cerebellar ataxia, pyramidal spasticity, and neuropathy.

Purpose of the Study:

• To review the clinical characteristics of ARSACS.
• To detail the cerebellar pathology associated with ARSACS.
• To highlight recent research advancements and emerging questions in ARSACS, including novel therapeutic avenues.

Main Methods:

• Review of clinical features and neuropathological findings in ARSACS patients.
• Examination of cerebellar atrophy, Purkinje cell loss, and associated neurodegeneration.
• Discussion of recent investigative approaches, such as patient-derived induced pluripotent stem cells.

Main Results:

• Neuropathology reveals cerebellar atrophy (superior and anterior vermis), Purkinje cell death, pyramidal tract degeneration, cortical atrophy, motor neuron loss, and demyelinating neuropathy.
• Significant progress in understanding ARSACS pathogenesis over the past two decades.
• Patient-derived induced pluripotent stem cells offer promising avenues for future research and discovery.

Conclusions:

• ARSACS presents with a distinct pattern of cerebellar and neurological deficits.
• Current understanding of ARSACS pathogenesis has advanced, though effective therapies remain unavailable.
• Emerging research, particularly stem cell-based strategies, holds potential for future ARSACS treatments.